Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SDS Biotech’s sales ahead in first half

Japanese agrochemical company SDS Biotech recorded sales of ¥4,826 million ($63 million) in the six months ended June 30th 2011, up 3.3% compared with the same period last year. However, operating income fell by 54.2% to ¥166 million ($2 million). Fungicide sales increased by 5.2% to ¥2,022 million ($26 million). There were strong sales in the Philippines, but domestic sales declined. Paddy rice herbicides were up 1.2% to ¥1,520 million ($20 million). Good sales in South Korea were offset by lower sales in Japan due to increasing competition from other companies’ new products, SDS Biotech says. Sales of non-crop pesticides were up 23.1% to ¥931 million ($12 million), with growth in the domestic and overseas markets. Insecticides fell 26.5% to ¥256 million ($3 million), while other products were down 31% to some ¥95 million ($1 million). The company forecasts annual sales growth of 2.4% to ¥11,700 million ($152 million – Agrow No 619, p 8).

Topics

What to read next

UsernamePublicRestriction

Register

AG012190

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel